Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Pluvia's Fist.com - Pluvia's Plays & Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: Pluvia who wrote (1737)	4/7/2006 9:54:17 AM
From: Pluvia	Respond to of 1766

LVRO - 7 for 1 forward split; ~ LVRO brother of VSGN (we think LVRO technology is superior to VSGN, and LVRO therapy produces same result and uses same mechanism of action as VSGN therapy) ~ VSGN PIII Results in May bring instant value to LVRO ~ LVRO has beeter product than VSGN ~ Own some LVRO now and take profits from VSGN win in May to buy more LVRO. All comments are the express opinion of the Author(s) do your own DD before investing; We own a substantial LVRO position. $$$$$$$ LipidViro Tech Declares 7 for 1 Stock Dividend Thursday April 6, 9:00 am ET SALT LAKE CITY, UT--(MARKET WIRE)--Apr 6, 2006 -- LipidViro Tech, Inc. (OTC BB:LVRO.OB - News) declares a stock dividend on its common stock, payable to common stock shareholders of record as of the close of business on April 17, 2006, or a date that is 10 days from the filing of Form 10b-17 with the NASD (the "Record Date"). The dividend requires a mandatory exchange of stock certificates. The dividend will consist of seven (7) shares of common stock payable for every issued and outstanding share of common stock, subject to the mandatory exchange. Therefore, for example, if a holder owns a round lot of 100 shares, he or she shall receive 700 shares in total after the mandatory exchange. The payment date for the stock dividend is set for May 5, 2006. According to the Warrant Agreement, the seven-for-one common stock dividend will affect the Class A and Class B warrant holders in similar fashion. For example, the owner of a round lot of 100 Class A or B Warrants shall now be able to purchase 700 shares upon exercise of the Warrant. Also according to the Warrant agreement, and as a result of the seven-for-one common stock dividend, the Exercise price of the Class A and B Warrant will also be reduced. The post-dividend Exercise price of the Class A Warrant will be reduced from $5.00 to $.7142; the post-dividend Exercise Price of the Class B Warrant will be reduced from $10.00 to $1.4285. Warrant holders do not need to exchange their Warrant certificates to receive these benefits; our Transfer Agent will automatically make these adjustments when Warrants are exercised. About LipidViro Tech: LipidViro Tech, Inc. is an early-stage biotechnology company engaged in research and commercial development of two primary platforms: d-OSAB Therapy, a treatment targeting cardiovascular disease and stroke; and PathPure, a purification process for production of pathogen-free biologics. During mid-2006 LipidViro is scheduled to commence a 100 patient Phase IIa study, treating patients who have suffered an ischemic brain stroke with LipidViro d-OSAB Therapy. LipidViro PathPure is a purification process for production of pathogen-free biologics. Biologics include animal and human-derived blood, plasma, sera, proteins, and cell concentrates. A wide variety of animal and human-derived biological fluids are routinely utilized in pharmaceutical development, human infusion and surgical procedures. For additional information, please visit our website. To sign up for LipidViro press releases go to www.lipidvirotech.com/news.html.